Sino Biopharmaceutical Limited Announces Comprehensive Breakthrough with Strong Innovation Pipeline and Global Expansion Strategy

Sino Biopharm is entering a period of comprehensive breakthrough. The most direct signal comes from the change in its revenue structure.

2025 Year,Sino Biopharm RevenueFirst Breakthrough300 100 million yuan, with the innovative drug business performing particularly outstandingly, reaching152.2 100 million yuan, a year-on-year increase of26.2%, contributing nearly half of the revenue. Looking back,2022 The company's revenue from innovative drugs was only67.5 billion yuan, accounting for of total revenue23.5%, achieving a qualitative leap in just three years.

Meanwhile, Sino Biopharm in transaction mergers and acquisitions, pipelineand has continued to achieve breakthroughs in layout and other aspects。

For example, in the first half of this year,JAK/ROCK InhibitorsRofacixtibNiAfter joining Sanofi, ChinaSino Biopharm Again Offers Zero Down PaymentEnteredGSK World's First Novel Drug for Hepatitis B CureBepirovirsen Commercialization rights in China.ThisThese deals are by no means simple pipeline collaborations, but rather a stepping stone for Sino Biopharm to forge deep ties with pharmaceutical giants.

Capable of earning money, and also of spending it

As one of China’s pharmaceutical giants, Sino Biopharm’s profitability is beyond doubt. Its investment in Kexing Biopharm in previous years, which yielded returns exceeding RMB 10 billion, serves as testament to this. Today, with its innovative drug business gradually entering the harvest period, Sino Biopharm’s performance has continued to rise, demonstrating increasingly robust growth momentum.

2025 year, Sino Biopharm's revenue exceeded for the first time300 billion yuan, reaching318.3 100 million yuan, a year-on-year increase of10.3%. Among them, the innovative drug business performed particularly well, surging26.2% To152.2 billion yuan, with its proportion of total revenue also achieving a leap,From2022 Year's23% Increased to48%。

Thanks to its robust self-sustaining cash flow and enhanced investment returns, Sino Biopharm maintains a substantial financial reserve, as of2025 Year12 Month31 day, itsCapital reserves amount to330 100 million yuan。

However, generating revenue alone is not enough; what truly sets Sino Biopharm apart is its willingness to invest heavily and make bold bets on long-term strategic tracks.

2025 Year7 month, Sino Biopharm5 net cost of USD 100 million, toLixin Pharmaceuticalsbrought under its wing. This deal not only enabled Sino Biopharm to acquire a portfolio of bispecific antibodies,ADC innovative pipeline and technology platforms in the field, further pioneering domesticallybig pharmaAcquisition of Local Companiesbiotech pioneering.

It is worth mentioning that Lixin Pharma has successively collaborated withMerck & Co. and AstraZeneca have reached out-licensing agreements, involving the products respectivelyPD1/VEGF Bispecific AntibodyLM-299、GPRC5D ADCNew DrugLM-305. Currently, Liming has received9.43 hundred million USD in upfront and milestone payments.

Source: Official Website of Sino Biopharm

2026 At the beginning of the year, Sino Biopharm once again took action, investing12 acquired Hejia for hundreds of millions of yuan, this time it is targetingSmall Nucleic Acid Sector. As a domesticsiRNA A rising star in the field, Hejia boasts a robust pipeline of oligonucleotide products, including candidates with the potential for once-yearly dosing.Lp(a) TargetedsiRNA MedicationKylo-11、APOC3 TargetedsiRNA DrugKylo-11, and intrahepatic deliveryMVIPDual-Target TechnologyDPP. Neural DeliveryNSDP and Fat DeliveryASDP Key Core Technology Platform.

Xie Qirun, Chairman of the Board of Sino Biopharm, publicly stated in an interview that the company sets aside several hundred million US dollars each year for mergers and acquisitions. In the future,Sino Biopharm is expected to take a more proactive approach to integrating high-quality external assets into its portfolio through mergers and acquisitions, collaborations, and other strategic initiatives.. This is also big pharma ToMNC An indispensable stage of advancement.

Innovative Pipeline, Accelerating Growth

If performance and cash flow determine whether a pharmaceutical company can sustain its investment, thenThe quality of the innovative pipeline determines its eligibility to advance to the next round of competition., and how far it can ultimately go in the future.

Sino Biopharm at2015 began its innovative transformation in [year], and after more than a decade of continuous, substantial investment, it has already10 new drugs have been launched onto the market, including 6 a self-developed new drug and4 Introduction of New Drugs. Notably, more than half of these products received approval in the past two years.

New Drugs Approved for Marketing by Sino Biopharm in Recent Years

Source: DXYInsight Database

Anlotinib is the first small-molecule novel anti-tumor drug independently developed by Sino Biopharm in China, since2018 Since its listing, it has been approved for11 indications, covering lung cancer, liver cancer, renal cell carcinoma, endometrial cancer, soft tissue sarcoma, and others, many of which involve combination regimens with bemisuzumab and penpulimab.

In terms of market performance, although no official data has been disclosed, some securities firms estimate that the sales revenue of Anlotinib exceeded in its first year on the market.10 100 million yuan,2019 Rapid annual growth to28 100 million yuan, and in recent years it has stabilized at30 Exceeding RMB 100 million, it is undoubtedly the flagship product of Sino Biopharm.

It is also worth mentioning Kumoxyli and Lovaxitinib, which are independently developed by Sino Biopharm. The former belongs toThe world's first approved for market launchCDK2/4/6 Inhibitor, the latter this year3 licensed to Sanofi in May, with a total transaction value of up to15.3 100 million USD.

However, the biggest highlight of Sino Biopharm still lies in its subsequent pipeline reserves. ItOn the one hand, we continue to consolidate our existing advantages; on the other hand, we constantly supplement with new mechanisms, new targets, and new technology platforms.

According to statistics, Sino Biopharm currently has more than 130 new drug pipelines in clinical development, with a key focus on oncology and liver diseases./Metabolism, Respiratory, Surgery/Four Major Therapeutic Areas in Analgesia, Involving Small Molecules, Monoclonal Antibodies, Bispecific Antibodies, and Antibody Fusion Proteins,ADC、PROTAC, small nucleic acid drugs and other drug types.

Source: Sino Biopharm Official Website

Specifically, in the field of oncology, Sino Biopharm is not limited to a single target or a single product, but ratherStrategic Deepening in High-Prevalence Cancers, Including Lung Cancer, Breast Cancer, and Gastrointestinal Tumors。

For example, in the field of lung cancer, Sino Biopharm has laid out a multi-target receptor tyrosine kinase inhibitor AL2846 and a CCR8 monoclonal antibody, Kefeqibaimab.PD-1/VEGF bispecific antibody LM-299, EGFR/c-Met Bispecific AntibodiesTQB2922、EGFR/c-Met Bispecific AntibodyADC TQB6411, etc., targeting drug resistance and the need for treatment across all lines.

In the field of breast cancer, TQB2930, a HER2 bispecific antibody, is undergoing clinical studies targeting subpopulations with HER2-positive and HER2-low expression. TQB2102AsHER2 Bispecific AntibodyADC, with indications covering multiple breast cancer subtypes, including HER2-positive, HER2-low, HR-positive/HER2-negative, and triple-negative.

Source: Sino Biopharm Official Website

In the fields of liver disease and cardiovascular care, Sino Biopharm’s strategy isLeveraging Strengths in Traditional Liver Disease to Expand into the Broader Market for Chronic Metabolic Diseases. For example, targetingMetabolic Dysfunction-Associated Steatohepatitis（MASH）, laid outPan-PPAR AgonistsLanifibranor、FGF21 Fusion ProteinTQA2225 andTHR-β AgonistKylo-0603。Meanwhile, it leveragesHejia’s oligonucleotide platform has entered theLp(a), APOC3, and other cutting-edge cardiovascular targets, while successfully entering the weight loss and glucose metabolism markets through its GLP-1 pipeline.

In the respiratory field, Sino BiopharmFocus on In-Depth Development in Asthma and Chronic Obstructive Pulmonary Disease（COPD）、Major Indications such as Rhinitis. Currently, the company has four respiratory products advanced to the stage of marketing approval application or Phase III clinical trials. Among them,TQC3721 Inhalation Suspension is aA PDE3/4 inhibitor with dual potential for anti-inflammatory effects and airway relaxation is currently undergoing Phase III clinical trials for COPD;Bosakitug is a TSLP monoclonal antibody currently undergoing Phase III clinical trials for asthma and chronic rhinosinusitis with nasal polyps.

Finally, in the surgery/analgesia sector, Sino Biopharm does not pursue hyped targets; instead, it has strategically positioned itself around unmet clinical needs by developing TRD205, a novel drug for postoperative pain, neuropathic pain, and peripheral neuropathic pain, and TRD208, a novel drug for postoperative pain and general pain.

To Become a GlobalTOP30 Pharmaceutical Company

Sino Biopharm has ranked among the top 50 global pharmaceutical companies for several consecutive years. In 2025, the company secured the 39th position with a revenue of RMB 28.87 billion. Its best-selling products were Anlotinib, Magnesium Isoglycyrrhizinate, and Calcitriol. Its next goal isTo rank among the global TOP30 pharmaceutical companies by 2033。

Sino Biopharm Global Ranking

Source: Compiled by DXY Insight

For Sino Biopharm, achieving this goal cannot rely solely on the Chinese market and volume growth of a few products; it also requiresStepping onto the International Stage: Bringing More New Drugs to the Global Market。

Xie Qirun, Chairman of the Board, explicitly stated that 2026 marks the first year of the company’s new decade-long strategy, with globalization as the core keyword for this phase. In the areas of biosimilars and generic drugs, Sino Biopharm will prioritize strategic deployment in Southeast Asia, South America, Europe, and the broader Asian market.

Regarding its innovative drug pipeline, Sino Biopharm will primarily seek collaborations with large multinational pharmaceutical companies and international biotech firms. Data from the Insight database shows that since 2020, the company has completed six license-out deals, partnering with companies such as AstraZeneca, Merck & Co., and Sanofi.

Sino Biopharm has built a robust pipeline of promising assets, with the next major business development deal just around the corner.

Reference Sources:

1. Sino Biopharm's Official Website, Official WeChat Account, and Financial Reports

2. Insight Database

3. Exclusive Interview with Xie Xin of Sino Biopharm: Becoming a Top 30 Global Pharmaceutical Company by 2033 (Yixian Insight)

Editor: Yueya

Cover source:ZCOOL Hello

Disclaimer:This article is for informational purposes only, does not represent the position or views of Insight, and does not constitute a recommendation or introduction to treatment plans. If needed, please consult and contact legitimate medical institutions.